Risperidone approved for the treatment of serious behavioral problems in children with autism

Journal of Child and Adolescent Psychiatric Nursing

Volumn 20, Issue 3, 2007, Pages 188-190

  Scahill, Lawrence ^a   Koenig, Kathleen ^b   Carroll, Deirdre H ^c   Pachler, Maryellen ^b  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

ARTICLE; AUTISM; BEHAVIOR DISORDER; CHILD; CHILD PSYCHIATRY; HUMAN; LEGAL ASPECT; PSYCHOLOGICAL ASPECT; UNITED STATES;

ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; CHILD BEHAVIOR DISORDERS; CHILD PSYCHIATRY; HUMANS; RISPERIDONE; UNITED STATES;

EID: 35048859960     PISSN: 10736077     EISSN: 17446171     Source Type: Journal    
DOI: 10.1111/j.1744-6171.2007.00112.x     Document Type: Note

References (10)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Journal of Clinical Psychiatry, 65 (2), 267-272.
2. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders, TR Edition. Washington, DC: Author.
3. Fombonne, E. (2003). The prevalence of autism. Journal of the American Medical Association, 289 (1), 87-89.
4. Martin, A., Scahill, L., Anderson, G. M., Aman, M., Arnold, L. E., McCracken, J., et al. (2004). Weight and leptin changes among risperidone-treated youths with autism: Six-month prospective data. American Journal of Psychiatry, 161 (6), 1125-1127.
5. McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., Davies, M., et al. (2005). Risperidone for the core symptom domains of autism: Results from the RUPP Autism Network Study. American Journal of Psychiatry, 162, 1142-1148.
6. Research Units on Pediatric Psychopharmacology Autism Network. (2002). Risperidone in children with autism for serious behavioral problems. New England Journal of Medicine, 347 (5), 314-321.
7. Research Units on Pediatric Psychopharmacology Autism Network. (2005). Risperidone treatment of autistic disorder: longer term benefits and blinded discontinuation after six months. American Journal of Psychiatry, 162, 1361-1369.
8. Scahill, L., McCracken, J. T., McDougle, C. J., Aman, M., Arnold, L. E., Tierney, E., et al. (2001). Methodological Issues in designing a multisite trial of risperidone in children and adolescents with autism. Journal Child and Adolescent Psychopharmacology, 11, 377- 388.
9. U.S. Food and Drug Administration. (2006). New indication for risperidone. www.fda.gov/cder/foi/lab. accessed March 1, 2007.
10. Williams, S. K., Scahill, L., Vitiellio, B., Aman, M. G., Arnold, L. E., McDougle, C. J., et al. (2006). Risperidone and adaptive behavior in children with autism. Journal of American Academy of Child and Adolescent Psychiatry, 45 (4), 431-439.